Viking Therapeutics (VKTX) Q1 FY26 earnings call

Viking Therapeutics reported significant progress in its obesity franchise during Q1 FY26, completing enrollment for both subcutaneous VK2735 Phase III trials and the maintenance dosing study. The company plans to initiate Phase III development for oral VK2735 in Q4 FY26, emphasizing optionality in treatment regimens. An IND was filed for the novel amylin receptor agonist VK3019, with Phase I initiation expected shortly, further diversifying the pipeline. The company also strengthened its commercialization strategy with a new Chief Commercial Officer and maintains a strong balance sheet to fun